Noemi Reguart

🔜 #ELCC26 @myESMO 🇩🇰 🔥Defining the limits of surgery in lung cancer ☑️ #Segmentectomy #StageIII #Resectability 🎙️Chair: @IsaOpitz Dr. Kenji Suzuki @OncoAlert @Larvol #LCSM

ALL IN at #TexasLung26! 🃏 The first-ever Texas Lung Hold 'Em debate "Surgical vs Non-surgical Approaches to Early-Stage Lung Cancer" is coming to ACL Live and the stakes couldn't be higher! Dealing the cards: Dr. @JSabari Perioperative Therapy and Surgery: Dr. @BrendonStilesMD Definitive Chemoradiation and Consolidation: Dr. @SalmaJabbour1 Pit bosses Drs. @StephenVLiu & Tina Cascone watching the action! Who's got the winning hand? Join us on April 9-11 in Austin, TX to find out. → na2.hubs.ly/H04lqsy0 #LungCancer #ThoracicOncology

👉 Come for the science, stay for the connections. Join the #LungOncology community at #ELCC26 this March in Copenhagen, onsite and online. 🔗 Save your place: ow.ly/Mrye50Yrm0V #esmomeetings @NReguart

Data on izalontamab brengitecan (iza-bren, EGFR-HER3 bispecific ADC) in AGA+ NSCLC (excluding common EGFR, reported separately) after standard treatment @JCO_ASCO. In EGFRex20 RR 69.2%, PFS 10.5m. HER2 RR 52.9%, PFS 7.5m. Only 1 case of ILD (G2). ascopubs.org/doi/10.1200/JC…

Registration open for #DCLung26 on 10/10/26 - with 77 expert multi-disciplinary faculty from the US & abroad, this will be our biggest yet. High yield talks with engaging panel discussions on how to implement new standards of care and best practice! medstarhealth.org/dclung

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial | Nature Communications nature.com/articles/s4146…

🫁 I-STOP: Discontinuing ICIs at 2 Years in Advanced NSCLC. Real-world multicenter study (n=173) of advanced NSCLC with disease control after ≥24 months of single-agent PD-1/PD-L1 inhibitors. OS: not reached in either group HR 1.22 (95% CI 0.50–2.95), p=0.66 PFS: 35.6 m (stop) vs NR (continue) HR 2.16 (95% CI 1.04–4.48), p=0.035 Higher progression risk if PD-L1 ≤50%, brain mets, ECOG ≥1, KRAS+. Rechallenge ORR 62.5%. Late G3–4 irAEs 3.5%. 2-year discontinuation appears feasible in selected pts, but not for all. 📖 European Journal of Cancer DOI 👉🏻 doi.org/10.1016/j.ejca… #CánCare #NSCLC #immunotherapy #thoraciconcology #lcsm

New ESMO/ESTRO consensus statements on safety of combining targeted therapy and radiation @ESMO_Open. For most scenarios, recommendation is to interrupt TKI therapy during radiation @myESMO @ESTRO_RT @PrelajArsela esmoopen.com/article/S2059-…

⭕ Nuevo episodio de LUNGPOD. 🫁 En este capítulo analizamos en profundidad las implicaciones clínicas y biológicas de la mutación BRAF en el CPNM. 🧑‍⚕️ Contamos con la participación de: ➡️ @charocampelo , (CHUAC) ➡️ @margamajem , (Hospital de la Santa Creu i Sant Pau de Barcelona) 🙌 Un diálogo clave para entender cómo la biología tumoral está redefiniendo la oncología de precisión. En colaboración con Pierre Fabre 👉 Escúchalo aquí: gecp.org/episodio-11-mu…

#LungCancerConsidered Dr. @StephenVLiu is joined by @sara_pilotto & Dr. Jonathan Riess to tackle a complex case of metastatic EGFR exon 19 NSCLC with discordant biomarkers & brain metastases. - Osimertinib vs FLAURA2 - CNS considerations - MARIPOSA & sequencing at progression Listen now: bit.ly/4ridnLO #LungCancer #EGFR #NSCLC

🚨 Check our Top 10 #LungCancer abstracts for ELCC 2026! We've hand-picked the must-see sessions with times & presenters. 🗓️ Stay on track in Copenhagen and simply import these directly to your calendar by clicking this link: lungsummit.org/elcc2026.ics Which lung abstracts are your favorites at ELCC26 #LCSM @IASLC @myESMO

@fcounago @NReguart A real pleasure to take part in this discussion #DialogosByAZLung. Multidisciplinary dialogue is key as we integrate the #LAURA data into the management of unresectable Stage III EGFR-mutated NSCLC. Thanks to @NReguart @fcounago and Sara Montemuiño for such an enriching exchange

Results with ORCHARD cohort of first-line datopotamab deruxtecan (Trop2 ADC) plus osimertinib in EGFR NSCLC @Annals_Oncology. At 6mg/kg, RR 36%, PFS 11.7m, DOR 20.5m, OS 26.2m - impressive but 76% G3+ AEs, 59% dose reduced, and ILD seen in 15%. annalsofoncology.org/article/S0923-…

🎙️ Today at #DialogosByAZLung Discussed survival in unresectable Stage III #EGFRm #NSCLC in the #LAURA era 🔬⚡ Incredible panelists & truly multidisciplinary discussion @NReguart #LungCancer #StageIII #RadiationOncology

If you looking for a short musical interlude? ➡️take a few minutes and listen to my brilliant #RadOnc colleaugues @HenryParkMD on🎻and Dr Andreas Rimner on🎹in this recording from the opening of #WCLC25 in #Barcelona @IASLC @DrJNaidoo @NReguart @IsaOpitz @UmbertoMalapel1 youtu.be/I30wPy_8QGo?si…

Are you interested for a deep-dive in early stage #NSCLC including perioperative IO/targeted, ADCs and future trial design? Don't miss the @myESMO advanced course in #Athens on 23-24th April chaired by @peters_solange , @ElinardouHelena and myself Register: 👉lnkd.in/due7fgRi Deadline: 18 March 2026 @OncoAlert #some #LCSM

Press release 🚨 Phase 3 LIBRETTO-432 meets primary endpoint: adjuvant selpercatinib improves iaEFS in early-stage RET+ NSCLC vs placebo. OS trending favorably; safety as expected.

Se marca un hito en la #CirugíaTorácica: primera colaboración SEPAR–SECT en un documento de consenso sobre estadificación mediastínica invasiva perioperatoria en CPNM. Un paso histórico para unificar criterios y fortalecer el trabajo conjunto. #SEPAR #SECT #ReunionInviernoSEPAR

Just published @NatureMedicine Repotrectinib in NTRK fusion + advanced solid tumors: results from a phase 1/2 trial TRIDENT-1. @BenjaminBesseMD. Durable systemic and IC activity, including TKI-pretreated patients and solvent-front mutations. nature.com/articles/s4159…

In a new ILCN article, Dr. @StephenVLiu highlights the potential role for zenocutuzumab as a first-line therapeutic option for patients with NRG1-positive cancers. Read now: bit.ly/3O1A09h